Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic
Status PubMed-not-MEDLINE Jazyk angličtina Země Švýcarsko Médium electronic
Typ dokumentu časopisecké články
PubMed
38673576
PubMed Central
PMC11051211
DOI
10.3390/jcm13082303
PII: jcm13082303
Knihovny.cz E-zdroje
- Klíčová slova
- COVID-19, Czech Republic, SARS-CoV-2, molnupiravir, real-world data, treatment of COVID-19,
- Publikační typ
- časopisecké články MeSH
Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of progression to severe disease requiring hospitalization. In this observational, retrospective study, we aimed to describe the characteristics and healthcare resource utilization in non-hospitalized, adult COVID-19 patients prescribed MOV in the Czech Republic between 1 January and 30 April 2022. Methods: A total of 621 patients were included and followed up with for 28 days. Results: The median age was 68.0 (20-99) years, 77.8% were overweight or obese, 14.1% smoked, and 85.7% were vaccinated. The overall cumulative incidence (95% CI) of all-cause hospitalization was 0.71 (0.37; 1.24) per 1000 person years or 1.9%, with similar rates across sexes, age groups, BMI category, multimorbidity category, polypharmacy category, and COVID-19 vaccination status. Among patients reported hospitalized, oxygen-based resources were not observed, and no deaths occurred. Conclusions: These data describe the characteristics and healthcare resource utilization in Czech MOV-treated patients whose clinical characteristics may put them at increased risk of severe disease.
Center for Observational and Real World Evidence Merck and Co Inc Rahway NJ 07065 USA
Infectious Disease Department Krajská Zdravotní a s 400 11 Ústí nad Labem Czech Republic
Institute of Biostatistics and Analyses Ltd 625 00 Brno Czech Republic
Zobrazit více v PubMed
WHO . WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19. WHO; Geneva, Switzerland: 2020.
Cucinotta D., Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91:157–160. doi: 10.23750/abm.v91i1.9397. PubMed DOI PMC
Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 Pandemic. [(accessed on 12 May 2023)]. Available online: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic?adgroupsurvey={adgroup-survey}&gclid=CjwKCAjwx_eiBhBGEiwA15gLNyFmCJcg_TjejCpwXJLoL3v3eL4OZQ9MQHBG_vVvswMxi1uJ1jOGKhoCZ2AQAvD_BwE.
[(accessed on 12 May 2023)]. Available online: https://covid19.who.int/
Nurchis M.C., Pascucci D., Sapienza M., Villani L., D’Ambrosio F., Castrini F., Specchia M.L., Laurenti P., Damiani G. Impact of the Burden of COVID-19 in Italy: Results of Disability-Adjusted Life Years (DALYs) and Productivity Loss. Int. J. Environ. Res. Public Health. 2020;17:4233. doi: 10.3390/ijerph17124233. PubMed DOI PMC
Socio-Economic Impact of COVID-19. United Nations Development Program. [(accessed on 5 February 2023)]. Available online: https://www.undp.org/asia-pacific/socio-economic-impact-covid-19?utm_source=EN&utm_medium=GSR&utm_content=US_UNDP_PaidSearch_Brand_English&utm_campaign=CENTRAL&c_src=CENTRAL&c_src2=GSR&gclid=CjwKCAiAxP2eBhBiEiwA5puhNVpfYhFDzaJGoINdiIeVfTKl82UfvFSiaw9nNbnSYMWlaebuM2W9QxoC0FwQAvD_BwE.
Peterson O., Thankom A. Spillover of COVID-19: Impact on the Global Economy. Munich Personal RePEc Archive Paper No. 99850. 26 April 2020. [(accessed on 12 May 2023)]. Available online: https://mpra.ub.uni-muenchen.de/99850/
Cizek M. Europe Versus Coronavirus—The Czech Republic: Masks, but for How Long? Analyses 20 May 2020. [(accessed on 12 May 2023)]. Available online: https://www.institutmontaigne.org/en/analysis/europe-versus-coronavirus-czech-republic-masks-how-long.
EURegioDataStories, the 8th Cohesion Report. [(accessed on 12 May 2023)]. Available online: https://cohesiondata.ec.europa.eu/stories/s/The-regional-impact-of-COVID-19/24gj-n8r2/
Sharma K., Koirala A., Nicolopoulos K., Chiu C., Wood N., Britton P.N. Vaccines for COVID-19: Where Do We Stand in 2021? Paediatr. Respir. Rev. 2021;39:22–31. doi: 10.1016/j.prrv.2021.07.001. PubMed DOI PMC
European Centre for Disease Prevention and Control, COVID-19 Vaccine Tracker. [(accessed on 12 May 2023)]. Available online: https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab.
Sheahan T.P., Sims A.C., Zhou S., Graham R.L., Pruijssers A.J., Agostini M.L., Leist S.R., Schäfer A., Dinnon K.H., 3rd, Stevens L.J., et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 2020;12:eabb5883. doi: 10.1126/scitranslmed.abb5883. PubMed DOI PMC
Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V., Martín-Quirós A., Caraco Y., Williams-Diaz A., Brown M.L., et al. Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N. Engl. J. Med. 2022;386:509–520. doi: 10.1056/NEJMoa2116044. PubMed DOI PMC
Centers for Disease Control and Prevention People with Certain Medical Conditions. [(accessed on 21 June 2022)]; Available online: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html.
Ministry of Health, Czech Republic, Decision. [(accessed on 12 May 2023)]. Available online: https://www.mzcr.cz/wp-content/uploads/2021/12/Rozhodnuti-o-docasnem-povoleni-distribuce-vydeje-a-pouzivani-leciveho-pripravku-LAGEVRIO.pdf.
FDA FactSheet. [(accessed on 12 May 2023)]; Available online: https://www.fda.gov/media/155050/download.
Lexicomp. [(accessed on 12 May 2023)]. Available online: https://www.wolterskluwer.com/en/solutions/lexicomp.
University of Liverpool. [(accessed on 12 May 2023)]. Available online: https://www.covid19-druginteractions.org/checker.
De Vito A., Colpani A., Bitti A., Zauli B., Meloni M.C., Fois M., Denti L., Bacciu S., Marcia C., Maida I., et al. Safety and efficacy of Molnupiravir in SARS-CoV-2 infected patients: A real life experience. J. Med. Virol. 2022;94:5582–5588. doi: 10.1002/jmv.28011. PubMed DOI PMC
Streinu-Cercel A., Miron V.D., Oana A.A., Irimia M., Popescu R.S., Daramus I.A., Motoi M.M., Ceapraga G.J., Sandulescu Real-World Use of Molnupiravir in the Treatment of Outpatients with SARS-CoV-2 Infection—A Patient Profile Based on the Experience of a Tertiary Infectious Disease Center. Pharmaceuticals. 2022;15:1065. doi: 10.3390/ph15091065. PubMed DOI PMC
Kimata M., Watanabe A., Yanagida Y., Kinoshita D., Maekawa S. Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-Marketing Surveillance in Japan. Infect. Dis. Ther. 2023;12:1119–1136. doi: 10.1007/s40121-023-00782-5. PubMed DOI PMC
Prajapati G., Das A., Yezhou S., Fonseca M. Hospitalization Among Patients Treated with Molnupiravir: A Retrospective Study of Administrative Data. Clin. Ther. 2023;45:957–964. doi: 10.1016/j.clinthera.2023.07.018. PubMed DOI
Ministry of Health, Czech Republic, COVID-19: Denní přehled testů, Prokázaných nákaz, Hospitalizací a JIP. [(accessed on 12 May 2023)]. Available online: https://onemocneni-aktualne.mzcr.cz/api/v2/covid-19.
Butler C.C., Hobbs F.D.R., Gbinigie O.A., Rahman N.M., Hayward G., Richards D.B., Dorward J., Lowe D.M., Standing J.F., Breuer J., et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): An open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401:281–293. doi: 10.1016/S0140-6736(22)02597-1. PubMed DOI PMC
